Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887238 | 1.00 | MDM2 (0.50) | MDM2HDAC1HDAC2PTPN1IDO1 | |
| SCHEMBL31028497 | 0.92 | HDAC1 (0.51) | HDAC1HDAC2PTPN1IDO1MDM4 | |
| SCHEMBL29398876 | 0.92 | HDAC1 (0.51) | HDAC1HDAC2PTPN1IDO1MDM4 | |
| SCHEMBL5887452 | 0.90 | MDM2 (0.50) | MDM2HDAC1HDAC2PTPN1IDO1 | |
| SCHEMBL5887455 | 0.90 | MDM2 (0.50) | MDM2HDAC1HDAC2PTPN1IDO1 | |
| SCHEMBL2858929 | 0.90 | HDAC1 (0.49) | HDAC1HDAC2PTPN1IDO1MDM4 | |
| SCHEMBL7314631 | 0.90 | IDO1 (0.50) | HDAC1HDAC2PTPN1IDO1MDM4 | |
| SCHEMBL2858930 | 0.90 | HDAC1 (0.49) | HDAC1HDAC2PTPN1IDO1MDM4 | |
| SCHEMBL118297 | 0.89 | MDM2 (0.58) | MDM2MDM4TP53KMT2A | |
| SCHEMBL20766898 | 0.89 | MDM2 (0.58) | MDM2MDM4TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091373-B2 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20040024229-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-02-05 | — | — | US | disclosed |
| EP-1346971-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024229-A1 | Production method for biarylalanine | BCAT2, BCAT1, PAH | MDM2 605/4885HDAC1 1726/4885HDAC2 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.